Form 8-K - Current report:
SEC Accession No. 0001193125-23-146219
Filing Date
2023-05-16
Accepted
2023-05-16 17:28:00
Documents
15
Period of Report
2023-05-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d503983d8k.htm   iXBRL 8-K 30001
2 EX-99.1 d503983dex991.htm EX-99.1 17577
7 GRAPHIC g503983g0517021351974.jpg GRAPHIC 3867
  Complete submission text file 0001193125-23-146219.txt   213046

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amgn-20230516.xsd EX-101.SCH 3285
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20230516_def.xml EX-101.DEF 13055
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20230516_lab.xml EX-101.LAB 21657
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20230516_pre.xml EX-101.PRE 13762
9 EXTRACTED XBRL INSTANCE DOCUMENT d503983d8k_htm.xml XML 5294
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 23928839
SIC: 2836 Biological Products, (No Diagnostic Substances)